FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2610971372> ?p ?o ?g. }

• W2610971372 endingPage "186" @default.
• W2610971372 startingPage "179" @default.
• W2610971372 abstract "Background Epithelial ovarian cancer (EOC) is an aggressive and heterogeneous disease. <10% of EOC demonstrate HER2/neu 3+ receptor over-expression. However, moderate to low (i.e., 2+ and 1+) HER2/neu expression is reported in up to 50% of EOC. The objective of this study was to compare the anti-tumor activity of SYD985, a novel HER2-targeting antibody-drug conjugate (ADC), to trastuzumab emtansine (T-DM1) in EOC models with differential HER2/neu expression. Methods The cytotoxicity of SYD985 and T-DM1 was evaluated using ten primary EOC cell lines with 0/1+, 2+, and 3+ HER2/neu expression in antibody-dependent cellular cytotoxicity (ADCC), proliferation, viability and bystander killing experiments. Finally, the in vivo activity of SYD985 and T-DM1 was also studied in ovarian cancer xenografts. Results SYD985 and T-DM1 induced similar ADCC in the presence of peripheral blood lymphocytes (PBL) against EOC cell lines with differential HER2/neu expression. In contrast, SYD985 was 3 to 42 fold more cytotoxic in the absence of PBL when compared to T-DM1 (p < 0.0001). Unlike T-DM1, SYD985 induced efficient bystander killing of HER2/neu 0/1+ tumor cells when admixed with HER2/neu 3+ EOC cells. In vivo studies confirmed that SYD985 is significantly more active than T-DM1 against HER2/neu 3+ EOC xenografts. Conclusions SYD985 is a novel ADC with remarkable activity against EOC with strong (3+) as well as moderate to low (i.e., 2+ and 1+) HER2/neu expression. SYD985 is more potent than T-DM1 in comparative experiments and unlike T-DM1, it is active against EOC demonstrating moderate/low or heterogeneous HER2/neu expression." @default.
• W2610971372 created "2017-05-12" @default.
• W2610971372 creator A5001552783 @default.
• W2610971372 creator A5010339370 @default.
• W2610971372 creator A5014098371 @default.
• W2610971372 creator A5021257078 @default.
• W2610971372 creator A5024732018 @default.
• W2610971372 creator A5026827320 @default.
• W2610971372 creator A5027337412 @default.
• W2610971372 creator A5032849063 @default.
• W2610971372 creator A5036908259 @default.
• W2610971372 creator A5045777866 @default.
• W2610971372 creator A5046857977 @default.
• W2610971372 creator A5054033479 @default.
• W2610971372 creator A5061703014 @default.
• W2610971372 creator A5062471254 @default.
• W2610971372 creator A5065285949 @default.
• W2610971372 creator A5080849182 @default.
• W2610971372 creator A5084497328 @default.
• W2610971372 creator A5087069262 @default.
• W2610971372 date "2017-07-01" @default.
• W2610971372 modified "2023-10-02" @default.
• W2610971372 title "SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression" @default.
• W2610971372 cites W1984136423 @default.
• W2610971372 cites W2000028774 @default.
• W2610971372 cites W2000834365 @default.
• W2610971372 cites W2006621710 @default.
• W2610971372 cites W2010442254 @default.
• W2610971372 cites W2046793599 @default.
• W2610971372 cites W2062051005 @default.
• W2610971372 cites W2066263765 @default.
• W2610971372 cites W2069404284 @default.
• W2610971372 cites W2071115192 @default.
• W2610971372 cites W2076131513 @default.
• W2610971372 cites W2078454159 @default.
• W2610971372 cites W2091114184 @default.
• W2610971372 cites W2106767659 @default.
• W2610971372 cites W2125514858 @default.
• W2610971372 cites W2125744030 @default.
• W2610971372 cites W2125868040 @default.
• W2610971372 cites W2126945850 @default.
• W2610971372 cites W2133029659 @default.
• W2610971372 cites W2137763083 @default.
• W2610971372 cites W2139343978 @default.
• W2610971372 cites W2159967578 @default.
• W2610971372 cites W2161640106 @default.
• W2610971372 cites W2235523093 @default.
• W2610971372 cites W2416202632 @default.
• W2610971372 doi "https://doi.org/10.1016/j.ygyno.2017.04.023" @default.
• W2610971372 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5533304" @default.
• W2610971372 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28473206" @default.
• W2610971372 hasPublicationYear "2017" @default.
• W2610971372 type Work @default.
• W2610971372 sameAs 2610971372 @default.
• W2610971372 citedByCount "35" @default.
• W2610971372 countsByYear W26109713722017 @default.
• W2610971372 countsByYear W26109713722018 @default.
• W2610971372 countsByYear W26109713722019 @default.
• W2610971372 countsByYear W26109713722020 @default.
• W2610971372 countsByYear W26109713722021 @default.
• W2610971372 countsByYear W26109713722022 @default.
• W2610971372 countsByYear W26109713722023 @default.
• W2610971372 crossrefType "journal-article" @default.
• W2610971372 hasAuthorship W2610971372A5001552783 @default.
• W2610971372 hasAuthorship W2610971372A5010339370 @default.
• W2610971372 hasAuthorship W2610971372A5014098371 @default.
• W2610971372 hasAuthorship W2610971372A5021257078 @default.
• W2610971372 hasAuthorship W2610971372A5024732018 @default.
• W2610971372 hasAuthorship W2610971372A5026827320 @default.
• W2610971372 hasAuthorship W2610971372A5027337412 @default.
• W2610971372 hasAuthorship W2610971372A5032849063 @default.
• W2610971372 hasAuthorship W2610971372A5036908259 @default.
• W2610971372 hasAuthorship W2610971372A5045777866 @default.
• W2610971372 hasAuthorship W2610971372A5046857977 @default.
• W2610971372 hasAuthorship W2610971372A5054033479 @default.
• W2610971372 hasAuthorship W2610971372A5061703014 @default.
• W2610971372 hasAuthorship W2610971372A5062471254 @default.
• W2610971372 hasAuthorship W2610971372A5065285949 @default.
• W2610971372 hasAuthorship W2610971372A5080849182 @default.
• W2610971372 hasAuthorship W2610971372A5084497328 @default.
• W2610971372 hasAuthorship W2610971372A5087069262 @default.
• W2610971372 hasBestOaLocation W26109713722 @default.
• W2610971372 hasConcept C109316439 @default.
• W2610971372 hasConcept C121608353 @default.
• W2610971372 hasConcept C126322002 @default.
• W2610971372 hasConcept C150903083 @default.
• W2610971372 hasConcept C154317977 @default.
• W2610971372 hasConcept C159654299 @default.
• W2610971372 hasConcept C202751555 @default.
• W2610971372 hasConcept C203014093 @default.
• W2610971372 hasConcept C207001950 @default.
• W2610971372 hasConcept C2776872082 @default.
• W2610971372 hasConcept C2777325958 @default.
• W2610971372 hasConcept C2778087150 @default.
• W2610971372 hasConcept C2779786085 @default.
• W2610971372 hasConcept C2780427987 @default.
• W2610971372 hasConcept C40677261 @default.
• W2610971372 hasConcept C502942594 @default.

• next